Aimmune Therapeutics to Host Investor Symposium on Peanut Allergy Treatment with Leading Expert Allergists on Friday, December 1 Read more about Aimmune Therapeutics to Host Investor Symposium on Peanut Allergy Treatment with Leading Expert Allergists on Friday, December 1
Aimmune Therapeutics Announces Third Quarter 2017 Financial Results and Planned Retirement of CEO by the End of 2018 Read more about Aimmune Therapeutics Announces Third Quarter 2017 Financial Results and Planned Retirement of CEO by the End of 2018
Aimmune Therapeutics to Participate in Four Investor Conferences in November Read more about Aimmune Therapeutics to Participate in Four Investor Conferences in November
Aimmune Therapeutics Announces Publication in The Journal of Allergy and Clinical Immunology: In Practice of Positive AR101 Data from ARC001 Phase 2 Clinical Trial Read more about Aimmune Therapeutics Announces Publication in The Journal of Allergy and Clinical Immunology: In Practice of Positive AR101 Data from ARC001 Phase 2 Clinical Trial
Aimmune Therapeutics to Present Data on Peanut Allergy at ACAAI and PAAM Medical Meetings Read more about Aimmune Therapeutics to Present Data on Peanut Allergy at ACAAI and PAAM Medical Meetings
Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofi’s Dupilumab for Peanut Allergy Read more about Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofi’s Dupilumab for Peanut Allergy
Aimmune Therapeutics at BioCentury NewsMakers In The BioTech Industry Conference Read more about Aimmune Therapeutics at BioCentury NewsMakers In The BioTech Industry Conference
Aimmune Therapeutics to Participate in Three Investor Conferences in September Read more about Aimmune Therapeutics to Participate in Three Investor Conferences in September
Aimmune Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16th Read more about Aimmune Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16th
Aimmune Therapeutics Announces Second Quarter 2017 Financial Results Read more about Aimmune Therapeutics Announces Second Quarter 2017 Financial Results
